Skip to main content
PIRAMAL PHARMA LIMITED logo

PIRAMAL PHARMA LIMITED — Investor Relations & Filings

Ticker · PPLPHARMA ISIN · INE0DK501011 LEI · 3358006D6AL7PZ4U9T51 BSE.NS Manufacturing
Open in API
Filings indexed 367 across all filing types
Latest filing 2023-02-08 Regulatory Filings
Country IN India
Listing BSE.NS PPLPHARMA

About PIRAMAL PHARMA LIMITED

https://www.piramalpharma.com/

Piramal Pharma Limited provides a broad range of products and services across the drug lifecycle through three main business segments: Piramal Pharma Solutions, Piramal Critical Care, and Consumer Healthcare. Piramal Pharma Solutions operates as an integrated Contract Development and Manufacturing Organization (CDMO), offering end-to-end services from drug discovery and development to commercial manufacturing of APIs and formulations. Piramal Critical Care focuses on complex hospital generics, holding a significant global market share in inhalation anesthetics, including Sevoflurane and Isoflurane, as well as injectable anesthesia and pain management therapies. The Consumer Healthcare division manages a diverse portfolio of over-the-counter brands such as Saridon, Lacto Calamine, and Tetmosol. The company leverages an extensive global manufacturing network to deliver specialized healthcare solutions worldwide.

Recent filings

Filing Released Lang Actions
Financial Result Updates
Regulatory Filings
2023-02-08 English
Outcome of Board Meeting
Regulatory Filings
2023-02-08 English
Board Meeting — Fund Raising
Capital/Financing Update Classification · 95% confidence The document is a short notice informing about a scheduled board meeting to consider a proposal for fund raising through equity shares or other securities. It references Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosures about board meetings. The document does not contain financial data or detailed report content but is an announcement of an upcoming board meeting and potential capital raising. Given the content and length (1744 characters), it fits best as a Capital/Financing Update (CAP) rather than a full report or regulatory filing. It is not a report publication announcement or certification. Therefore, the classification is CAP with high confidence.
2023-02-05 English
Updates
Major Shareholding Notification Classification · 95% confidence The document is a formal disclosure addressed to stock exchanges (BSE and NSE) regarding requests from entities currently classified as 'Promoter Group' to be re-classified as 'Public Shareholder' category. It references compliance with SEBI Listing Regulations, specifically Regulation 30 and 31A, which govern disclosures and re-classification of shareholding categories. The document is dated and signed by the Company Secretary, indicating it is an official announcement. There is no financial data, no report attached or referenced as being published, and no mention of voting results or management changes. The content is about shareholding classification changes, which fits the category of Major Shareholding Notification (MRQ). The document length is short (2861 characters), and it is not a report publication announcement or certification. Therefore, the best classification is Major Shareholding Notification (MRQ).
2023-02-02 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 90% confidence The document is a notification from Piramal Pharma Limited about an upcoming conference call with investors and analysts to discuss the Q3 and 9M FY2023 financial results. It includes details about the date, time, dial-in numbers, and registration link for the call. There is no actual financial data or detailed report content included, only an announcement of the event. The document length is 3576 characters, which is relatively short and consistent with an announcement rather than a full report or transcript. Therefore, this document is best classified as a Call Transcript (CT) announcement, but since it does not contain the transcript itself, it is an announcement of a conference call. However, the closest fitting category given the options is Call Transcript (CT) because it relates specifically to a conference call event. Confidence is high due to clear identification of the document purpose and content.
2023-02-01 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a short announcement dated 1st February 2023 addressed to stock exchanges (BSE and NSE) regarding the upcoming Board Meeting on 8th February 2023 to consider and approve the unaudited financial results for the quarter and nine months ended 31st December 2022. It also mentions the closure of the trading window. The document does not contain any financial data or detailed results but is a notification of an event related to financial reporting. The length is only 1766 characters, which is quite short and consistent with an announcement rather than a full report. Therefore, this document is best classified as a Regulatory Filing (RNS) since it is a general regulatory announcement about the board meeting and financial results approval, not the results themselves or a detailed report.
2023-02-01 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.